Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Promis Neurosciences Inc (OTC: ARFXF).

Full DD Report for ARFXF

You must become a subscriber to view this report.


Recent News from (OTC: ARFXF)

ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results Canada NewsWire TORONTO and CAMBRIDGE, MA, Aug. 29, 2018 TORONTO and CAMBRIDGE, MA , Aug. 29, 2018 /CNW/ -   ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company fo...
Source: Canada Newswire
Date: August, 29 2018 07:30
ProMIS Neurosciences to Present at 20th Annual Global Investment Conference
ProMIS Neurosciences to Present at 20th Annual Global Investment Conference Canada NewsWire TORONTO and CAMBRIDGE, MA, Aug. 22, 2018 TORONTO and CAMBRIDGE, MA , Aug. 22, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focu...
Source: Canada Newswire
Date: August, 22 2018 07:30
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
TSX: PMN; OTCQB: ARFXF Lack of PMN310 binding to amyloid deposits in Alzheimer's brain tissue may eliminate dose-limiting brain swelling seen with BAN2401 and aducanumab TORONTO , and CAMBRIDGE, MA , Aug. 21, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF),...
Source: PR Newswire
Date: August, 21 2018 07:30
ProMIS Neurosciences Announces Second Quarter 2018 Results
ProMIS Neurosciences Announces Second Quarter 2018 Results Canada NewsWire TORONTO and CAMBRIDGE, MA, Aug. 14, 2018 TSX: PMN; OTCQB: ARFXF TORONTO and CAMBRIDGE, MA , Aug. 14, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company fo...
Source: Canada Newswire
Date: August, 14 2018 07:30
ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018
TSX: PMN; OTCQB: ARFXF Encouraging results of recent clinical trials in Alzheimer's disease indicate importance of selectively targeting toxic amyloid-beta oligomers TORONTO and CAMBRIDGE, MA , Aug. 7, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a b...
Source: PR Newswire
Date: August, 07 2018 07:30
ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'
ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018' Canada NewsWire TORONTO and CAMBRIDGE, MA, July 31, 2018 TSX: PMN; OTCQB: ARFXF Key conference theme: targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer's ...
Source: Canada Newswire
Date: July, 31 2018 07:30
ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference
PMN310 Shows Potential for Best in Class Amyloid-Beta Oligomer Selectivity TORONTO and CAMBRIDGE, MA , July 10, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targetin...
Source: PR Newswire
Date: July, 10 2018 07:30
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS' shareholders show overwhelming support for all resolutions TSX:PMN; OTCQB: ARFXF TORONTO and CAMBRIDGE, MA , June 28, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (the "Corporation"), a biotechnology company focused on the discovery and development of precision...
Source: PR Newswire
Date: June, 28 2018 07:30
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Antibody Candidates Targeting Toxic Oligomers Implicated in Parkinson's Disease and Amyotrophic Lateral Sclerosis (ALS) Advance to the Final Stage of ProMIS Discovery Platform TSX:PMN; OTCQB: ARFXF TORONTO and CAMBRIDGE, MA , June 26, 2018 /PRNewswire/ - ProMIS Neurosciences, In...
Source: PR Newswire
Date: June, 26 2018 07:30
ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting
TORONTO and CAMBRIDGE, MA , June 20, 2018 /PRNewswire/ - ProMIS Neurosciences Inc. (the "Corporation") (TSX: PMN.TO) (OTCQB: ARFXF) would like to remind shareholders they have until 9:00 am (Toronto Time) on Monday June 25, 2018 to vote their shares for the upcoming Annual Gene...
Source: PR Newswire
Date: June, 20 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.165860.18080.1840.16573580,095
2018-12-130.15110.15720.15870.151172,000
2018-12-120.1550250.15110.15550.146187,137
2018-12-110.14340.14410.1510.143496,847
2018-12-100.150.147920.15860.1478117,260

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-145,00080,0956.2426Cover
2018-12-132,50072,0003.4722Cover
2018-12-114,00096,8474.1302Cover
2018-12-1046,500117,26039.6555Short
2018-12-0648,500118,07541.0756Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARFXF.


About Promis Neurosciences Inc (OTC: ARFXF)

Logo for Promis Neurosciences Inc (OTC: ARFXF)

ProMIS Neuorsciences Inc is a development stage biotech company that discovers and develops game changing precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimers disease AD and amyotrophic lateral sclerosis ALS .

 

 

 

Current Management

  • Elliot Goldstein / CEO, President
  • Steven Plotkin / Officer
  • Daniel E. Geffken / CFO
  • Johanne Kaplan / Chief Development Officer
  • Neil Cashman / Chief Scientific Officer
  • Kristi Lanier / Director, Fin.
  • Eugene Williams / Executive Chairman
  • Anthony J Giovinazzo / Independent Director, Audit Committee Member, Compensation Committee Member
  • Richard Gregory / Independent Director, Compensation Committee Member
  • Patrick Kirwin / Independent Director, Audit Committee Member
  • Johannes Minho Roth / Independent Director
  • William Wyman / Independent Director, Audit Committee Member, Compensation Committee Member

Current Share Structure

  • Market Cap: $70,856,647 - 03/12/2018
  • Issue and Outstanding: 220,058,534 - 11/08/2017

 


Recent Filings from (OTC: ARFXF)

Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 03 2018
Proxy Materials - Form of Proxy - 2016
Filing Type: Proxy Materials - Form of Proxy - 2016Filing Source: OTC Markets
Filing Date: November, 14 2017
OTCQB Certification - Certification
Filing Type: OTCQB Certification - CertificationFiling Source: OTC Markets
Filing Date: November, 14 2017
Notice of Change in Substantial Holder Interest - Early warning report 08122016
Filing Type: Notice of Change in Substantial Holder Interest - Early warning report 08122016Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Shareholders rights Plan 01222016
Filing Type: Supplemental Information - Shareholders rights Plan 01222016Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 08302017
Filing Type: Supplemental Information - Material Change report 08302017Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 08102017
Filing Type: Supplemental Information - Material Change report 08102017Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 05132016
Filing Type: Supplemental Information - Material Change report 05132016Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - Material Change report 04052016
Filing Type: Supplemental Information - Material Change report 04052016Filing Source: OTC Markets
Filing Date: November, 14 2017
Proxy Statement - Mgmt information Circular 2016
Filing Type: Proxy Statement - Mgmt information Circular 2016Filing Source: OTC Markets
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: ARFXF)

Daily Technical Chart for (OTC: ARFXF)


Stay tuned for daily updates and more on (OTC: ARFXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARFXF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARFXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ARFXF and does not buy, sell, or trade any shares of ARFXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/